Holen Sie sich die Stockscreener-App
15.89
4.47%
0.68
Schlusskurs vom Vortag:
$15.21
Offen:
$15.35
24-Stunden-Volumen:
1.05M
Relative Volume:
0.85
Marktkapitalisierung:
$2.72B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-6.0649
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
-0.44%
1M Leistung:
-12.36%
6M Leistung:
-19.99%
1J Leistung:
-46.66%
1-Tages-Spanne:
$15.14
$16.18
1-Wochen-Bereich:
$14.32
$16.43
52-Wochen-Spanne:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
15.89 | 2.65B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc.IMVT - Business Wire
Immunovant price target lowered to $57 from $58 at Citi - MSN
JP Morgan Lowers Price Target for Immunovant to $37, Maintains Overweight Rating - AInvest
IMVT: Analyst Jason Gerberry Lowers Price Target to $30, Maintains 'Buy' Rating - AInvest
Immunovant's Q1 Loss Narrower Than Expected, Pipeline In Focus - Barchart.com
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus - Yahoo Finance
Chart Patterns Forming a Bullish Setup in Immunovant Inc.Reliable Investment Entry Signals Confirmed by Charts - 선데이타임즈
What makes Immunovant Inc. stock price move sharplyWealth Tripler Trade List - newsyoung.net
Immunovant Reports Progress and Financial Results - TipRanks
Immunovant Posts 34% R&D Jump in Q1 - AOL.com
Immunovant Spends More To Move Key Drug Trials Forward - Finimize
Immunovant Pours More Into Trials And Investors Aren’t Flinching - Finimize
Stifel lowers Immunovant stock price target to $50 from $61, maintains Buy - Investing.com Canada
Assessing Immunovant's Strategic Expansion and Financial Viability Amid Widening Losses - AInvest
Immunovant's Fiscal Q1 Net Loss Widens - MarketScreener
Immunovant Posts 34% R&D Jump in Q1 - The Motley Fool
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
Immunology company Immunovant's Q1 net loss widens to $120.6 mln - MarketScreener
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 - The Manila Times
Immunovant Launches New Clinical Trials, Reports $599M Cash Position | IMVT Stock News - Stock Titan
Candlestick Reversal Detected on Immunovant Inc.’s ChartReal Time Alerts Based on AI Prediction Triggered - metal.it
Is Immunovant Inc. a growth stock or a value stockStrong return on investment - Jammu Links News
How does Immunovant Inc. compare to its industry peersAchieve rapid portfolio appreciation today - Jammu Links News
What are the technical indicators suggesting about Immunovant Inc.Massive wealth growth - Jammu Links News
Is Immunovant Inc. a good long term investmentFastest-growing stock picks - Jammu Links News
Should I hold or sell Immunovant Inc. stock in 2025Sky-high return potential - Jammu Links News
When is Immunovant Inc. stock expected to show significant growthTriple-digit growth rates - Jammu Links News
How volatile is Immunovant Inc. stock compared to the marketUnmatched market gains - Jammu Links News
What drives Immunovant Inc. stock priceCapitalize on market opportunities with confidence - Jammu Links News
What institutional investors are buying Immunovant Inc. stockOutperformance with explosive growth - Jammu Links News
Is it the right time to buy Immunovant Inc. stockFree Stock Movement Tracking - Jammu Links News
What catalysts could drive Immunovant Inc. stock higher in 2025Breakthrough wealth creation - Jammu Links News
Is Immunovant Inc. stock overvalued or undervaluedBuild a portfolio that outperforms the market - Jammu Links News
What are analysts’ price targets for Immunovant Inc. in the next 12 monthsOutstanding growth strategies - Jammu Links News
How does Immunovant Inc. generate profit in a changing economyFree Capital Growth Strategies - Jammu Links News
What analysts say about Immunovant Inc. stockCapitalize on market momentum for big wins - Jammu Links News
How many analysts rate Immunovant Inc. as a “Buy”Get daily updates on top-performing stocks - Jammu Links News
Why is Immunovant Inc. stock attracting strong analyst attentionMaximize gains with expert trading strategies - Jammu Links News
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
Immunovant Appoints Eric Venker as New CEO - The Globe and Mail
Immunovant appoints Eric Venker as CEO with new compensation agreement By Investing.com - Investing.com Canada
Momentum Screeners Rank Immunovant Inc. in Top 5 TodayReversal Alert Based on RSI Indicator Confirmed - metal.it
Immunovant Inc. Hits Oversold Level on RSI IndicatorProfit Focused Stock Screener Results Released - metal.it
Immunovant Inc. stock volume spike explainedFree Fast Return Equity Trade Forecast - Newser
Immunovant Inc. stock daily chart insightsFree Risk Controlled Short Term Trade Plans - Newser
Can momentum traders help lift Immunovant Inc.Chart Driven Entry Timing for Swing Trades - Newser
Immunovant Inc. Company Revenue and Profit Trends: A Deep DiveFree Real-Time Stock Data - metal.it
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):